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ciliopathies
Iker Sanchez-Navarro1,2, Luciana R. J. da Silva1,3, Fiona Blanco-Kelly1,2, Olga Zurita1,2, Noelia 
Sanchez-Bolivar1, Cristina Villaverde1,2, Maria Isabel Lopez-Molina4, Blanca Garcia-Sandoval4, 
Saoud Tahsin-Swafiri1, Pablo Minguez1, Rosa Riveiro-Alvarez1,2, Isabel Lorda1,2, Rocío 
Sanchez-Alcudia1,2, Raquel Perez-Carro1, Diana Valverde5, Yichuan Liu6,7, Lifeng Tian6, Hakon 
Hakonarson6,8,9, Almudena Avila-Fernandez1,2, Marta Corton1,2 & Carmen Ayuso1,2
Inherited syndromic retinopathies are a highly heterogeneous group of diseases that involve retinal 
anomalies and systemic manifestations. They include retinal ciliopathies, other well-defined clinical 
syndromes presenting with retinal alterations and cases of non-specific multisystemic diseases. The 
heterogeneity of these conditions makes molecular and clinical characterization of patients challenging 
in daily clinical practice. We explored the capacity of targeted resequencing and copy-number variation 
analysis to improve diagnosis of a heterogeneous cohort of 47 patients mainly comprising atypical cases 
that did not clearly fit a specific clinical diagnosis. Thirty-three likely pathogenic variants were identified 
in 18 genes (ABCC6, ALMS1, BBS1, BBS2, BBS12, CEP41, CEP290, IFT172, IFT27, MKKS, MYO7A, OTX2, 
PDZD7, PEX1, RPGRIP1, USH2A, VPS13B, and WDPCP). Molecular findings and additional clinical 
reassessments made it possible to accurately characterize 14 probands (30% of the total). Notably, 
clinical refinement of complex phenotypes was achieved in 4 cases, including 2 de novo OTX2-related 
syndromes, a novel phenotypic association for the ciliary CEP41 gene, and the co-existence of biallelic 
USH2A variants and a Koolen-de-Vries syndrome–related 17q21.31 microdeletion. We demonstrate 
that combining next-generation sequencing and CNV analysis is a comprehensive and useful approach 
to unravel the extensive phenotypic and genotypic complexity of inherited syndromic retinopathies.
Inherited syndromic retinopathies (ISR) are clinically and genetically heterogeneous diseases in which reti-
nal alteration is accompanied by systemic anomalies that can involve one or more systems, such as auditory, 
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neurological, musculoskeletal, renal, cardiac, and hepatic systems1,2. These disorders can be inherited in an 
autosomal recessive, autosomal dominant, X-linked, or mitochondrial fashion. Triallelism and oligogenic forms 
have also been described3. To date, ISRs have been related to at least 90 genes based on the Retinal Information 
Network database (RetNet, https://sph.uth.edu/retnet/).
ISRs include clinically well-defined syndromes such as ciliopathies4 (Alström5, Bardet-Biedl6, Joubert7, 
Senior-Løcken8, and Usher syndrome9), syndromes related to other cellular components (Cohen syndrome10 
and peroxisome biogenesis disorders [PBDs]11), and even extracellular molecular defects (Stickler syn-
drome)12. In other cases, patients present with diverse non-specific systemic symptoms and signs in which 
a clear clinical diagnosis cannot be easily achieved13. As many of these entities share medical and molecular 
features that hinder their clinical management and follow-up13, ISR diagnosis is quite difficult and challenging, 
and patients often visit various specialists over a period of years without a conclusive diagnosis being made. 
Thus, molecular characterization is essential for an accurate and definitive diagnosis and helps to guide repro-
ductive risk assessment, counseling, surveillance, management, and prognosis1,13. Our study may also pro-
vide clues for appropriate selection of patients to be enrolled in future clinical trials such as those examining 
gene-based therapies.
Traditional methods for mutation screening are costly and labor-intensive and entail a low molecular diag-
nostic rate, even for patients with a clear suspicion of ciliopathy14,15. Next-generation sequencing (NGS) is a 
cost-effective approach for the genetic diagnosis of retinal diseases16,17. Several studies have focused on spe-
cific retinal ciliopathies, such as Bardet-Biedl syndrome (BBS)18 and Joubert syndrome7,19–21, with a wide range 
of reported mutation detection rates depending on the number of targeted genes, NGS platform, and use of 
pre-screened or “naive” cases. In patients with complex atypical phenotypes, chromosomal microarray analysis 
may also be very useful for assessing contiguous gene deletion syndromes as a cause of disease co-occurrence22. 
To date, few authors have studied the role of copy number variations (CNVs) in retinal dystrophies (RD)23–27. We 
performed a molecular analysis using a custom targeted resequencing approach combined with CNV analysis in 
order to characterize a heterogeneous cohort of ISR patients whose specific disease had not yet been determined. 
Our results provide new insights into the genetic complexity of these diseases.
Results
A cohort of 47 genetically uncharacterized ISR cases underwent a comprehensive analysis of single-nucleotide 
variants (SNVs) and CNVs, based mainly on a custom targeted NGS for 121- gene panel of ISR-associated and 
candidate genes (Supplementary Table S1). The genes were selected based on previous associations with ISR 
reported in the literature, many of which showed a high proportion of associated phenotypes and appeared to be 
functionally related (Supplementary Fig. S1).
Patients were classified into 4 major phenotypic categories based on clinical features and suspected clinical 
diagnosis (Fig. 1): i) ciliopathies, including 10 cases with Alström, BBS, or Joubert syndrome; ii) ciliopathy-like, 
including 11 patients with RD and some ciliopathy-related systemic anomalies (polydactyly, obesity, diabetes, 
hearing, loss, and/or nephronophthisis); iii) other known syndromic retinopathies, a total of 5 patients with 
a clear diagnosis of either PBDs, Stickler syndrome, or pseudoxanthoma elasticum (PXE); iv) miscellanea, 
including 21 cases with heterogeneous phenotypes involving retinal disease with 1 or more non-specific sys-
temic features, such as congenital malformations, ataxia, dwarfism, intellectual disability (ID), or neuroendocrine 
alterations.
A total of 33 pathogenic or likely pathogenic variants were identified in 49% of patients (23/47) (Tables 1 
and 2 and Supplementary Table S2), including 30 SNVs and 3 CNVs in 18 different genes (ABCC6, ALMS1, 
BBS1, BBS2, BBS12, CEP41, CEP290, IFT172, IFT27, MKKS, MYO7A, OTX2, PDZD7, PEX1, RPGRIP1, USH2A, 
VPS13B, and WDPCP). Thirteen of the SNVs were novel (Supplementary Table S3), including 2 non-synonymous 
and 2 in-frame variants (ABCC6: p.(Leu495del), BBS12: p.(Ser440del), CEP41: p.(Ser2Phe), IFT27: p.(Tyr35Cys)), 
which were considered potentially pathogenic based on in silico prediction, evolutionary conservation of the 
wild-type residues, previous knowledge of ISR-associated genes, and disease co-segregation.
From the total identified variants, 23 were further considered likely causative in 14 cases based on pheno-
typic concordance, and also on co-occurrence with a second allele in recessive genes or the presence of de novo 
events in dominant genes (Table 1). Thus, we obtained a diagnosis rate of 30%, including known and likely 
disease-associated variants (Table 1 and Fig. 1). In terms of inheritance patterns, 86% of the cases had an auto-
somal recessive inheritance, 2 cases carried de novo autosomal dominant variants, and in one family, triallelism 
for BBS1 and MKKS was suspected. Additionally, in 9 cases (19%) which carried heterozygous likely pathogenic 
alleles in genes responsible for recessive RD (Supplementary Table S2), no second allele was found using NGS, 
multiplex ligation-dependent probe amplification (MLPA), and/or array–based comparative genomic hybridiza-
tion (aCGH).
Revision of Cases with Concordant Molecular Findings and Initial Clinical Diagnosis. Our 
approach confirmed the initial clinical suspicion in 9 cases. Based on our first phenotypic classification, we char-
acterized up to 70% of cases (7/10) with a clear phenotypic manifestation of ciliopathy and 40% of cases (2/5) 
presenting other well-defined ISRs (Fig. 1).
Three out of 4 cases with clinical suspicion of Alström syndrome carried biallelic causal ALMS1 variants 
(families RP-1232, RP-2177, and RP-2186, Table 1 and Fig. 2). Similarly, 3 out of 4 of the cases previously clas-
sified as BBS carried likely pathogenic variants in known BBS-associated genes (Table 1). In family RP-2069, 
which comprised 2 affected siblings with RP, neurodevelopment delay, obesity, and renal alterations (Table 1 
and Fig. 2), the index case was found to have two novel heterozygous likely pathogenic variants in IFT27 
(Supplementary Table S3), a splicing variant in exon 6 (c.350-2A>G), and a missense variant p.(Tyr35Cys), which 
affects a highly conserved residue located in a nucleotide-binding domain with GTPase activity28. In addition, 
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the IFT27-associated phenotype is clearly consistent with the clinical presentation of our family29. In sporadic 
case RP-2167, which had characteristic BBS-associated features (Table 1), we found 2 known heterozygous BBS2 
alleles, a nonsense variant30, and a synonymous change that had previously been reported in homozygosis as a 
cause of retinitis pigmentosa31. This silent variant, which was located at the last nucleotide of exon 3, likely abol-
ishes the canonical donor splice site by interfering with U1snRNA recognition. In the sporadic BBS case RP-2228, 
which carried 2 previously identified heterozygous variants in MKKS32 and BBS133, a second loss-of-function 
(LOF) allele in BBS1 was found by NGS analysis (Table 1). In this case, triallelism could not be completely con-
firmed, owing to an uninformative pedigree structure with only 1 affected patient (Fig. 2). In addition, we charac-
terized 1 of the 2 Joubert syndrome families in our cohort. Two affected siblings presenting with early-onset RD, 
cerebellar atrophy, late-stage renal failure, and ID (family RP-1814, Table 1) carried previously described biallelic 
LOF variants in CEP29034,35 (Fig. 2).
We also confirmed the clinical diagnosis of 2 families presenting with a clear non-ciliopathy retinal syndrome 
(Fig. 1). The sporadic case RP-1724, who was born to an endogamous couple and presented infantile Refsum 
disease, homozygously carried a PEX1 allele, p.(Gly843Asp), which is the most common causal allele in Zellweger 
syndrome spectrum disorders (ZSSD)36,37. Similar to other cases with this variant36,37, the patient exhibited a 
mild form of ZSSD with a progressive disease course. Finally, we studied an apparently pseudo-dominant family 
in which PXE has been suspected in 2 affected siblings and their father (V-0799, Fig. 2). All affected individu-
als showed a similar phenotype of angioid streaks, vision loss around 55 years, atrophic macular degeneration 
and dyschromatopsia. After NGS and segregation analysis, both affected siblings (II:1 and II:2) carried a novel 
homozygous in-frame deletion in the ABCC6 gene, namely p.(Leu495del) (Table 1 and Fig. 2). This variant affects 
a phylogenetically conserved amino-acid position, where a missense change had previously been described for 
this disease38 and was predicted as deleterious by in silico analysis. CNV depth-read and MLPA analysis ruled out 
whole-gene or multi-exon deletions in the ABCC6 gene in the family (Supplementary Fig. S2). In addition, hap-
lotype analysis of the ABCC6 locus and the surrounding genomic regions confirmed that an identity-by-descent 
(IBD) mechanism was involved in the homozygous transmission of the variant (Supplementary Fig. S2). This 
finding was clearly consistent with the highly endogamous ancestry of both parents. Thus, the suspected autoso-
mal dominant transmission of this variant has been clearly ruled out in this family, accordingly to which PXE is 
a well recognized autosomal recessive disorder39,40. Therefore, the apparent pseudo-dominance in this family is 
Figure 1. Clinical classification of patients with inherited syndromic retinopathies (ISR) and molecular 
findings obtained in this study. The two charts summarize initial and reassessed clinical classifications, 
before and after molecular testing, respectively. Four main phenotypic categories of cases were considered: i) 
clinically-defined ciliopathy syndromes, represented in dark blue color; ii) ciliopathy-like cases, in which retinal 
degeneration was found in association with multiple ciliopathy-like features (in light blue color); iii) patients 
with a clear diagnosis of a non-ciliopathy RD, represented in green, and iv) miscellaneous cases (in red color) 
with a variety of phenotypes that involved RD with one or more unspecific systemic symptoms, in which an 
obvious diagnosis could not be clearly established. The different levels of circles of the right chart (from inner 
to outside) reflect molecular yield depending on these 4 clinical categories and the mutated genes. Inner circle 
in grey shapes represents the fraction of solved (30%, 14/47) vs unsolved (70%, 33/47) cases after molecular 
testing. Second circle indicates the yield of molecular characterization based on the initial classification. Third 
level shows the causal genes found in this study and their respective color indicate the associated syndromic 
retinal disease. Outer level indicated the final classification of the solved cases. *CEP41, USH2A, and VSP13B 
cases, which were initially included in the miscellanea group, were re-classified after genetic testing. Dual 
diagnosis of USH2A biallelic pathogenic variants and de novo 17q21.31 mosonomy associated with Usher 
and Koolen de Vries syndromes, respectively. ALMS: Alström syndrome; BBS: Bardet-Biedl Syndrome; ID: 
Intellectual Disability; ISR: inherited syndromic retinopathies; RD: Retinal Dystrophy; SLS: Senior-Løcken 
syndrome; USH: Usher syndrome; ZSSD: Zellweger syndrome spectrum disorder.
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Family Initial Dx Final Dx Clinical Features Gene Allele 1 Allele 2
Other 
alterations Methods Segregation
Ciliopathies
RP-1232 Alström Alström
RP, hearing loss, 
obesity, diabetes, 
NPHP, hypogonadism, 
hypothyroidism, 
hyperinsulinemia, and 
acantosis nigricans
ALMS1 NM_015120.4:c.4252del;p.(Arg1418Glyfs*55)
NM_015120.4:c.4252del;
p.(Arg1418Glyfs*55) NGS Y (AR)
RP-2186 Alström Alström
Early RD, overweight, 
dilated cardiomyopathy, 
and diabetes
ALMS1 NM_015120.4:c.4477G>T;p.(Glu1493*)61
NM_015120.4: c.7571_7572del;
p.(His2524Argfs*11)61 NGS Y (AR)
RP-2177 Alström Alström CRD, hearing loss, and dilated cardiomyopathy ALMS1
NM_015120.4:c.808C>T;
p.(Arg270*)31
NM_015120.4:c.11618_116
19del;
p.(Ser3873Tyrfs*19)61
NGS na
RP-2069 BBS BBS
CRD, polydactyly, 
maturation and 
learning delay, obesity, 
and chronic renal 
failure
IFT27 NM_006860.4:c.104A>G; p.(Tyr35Cys) NM_006860.4:c.350-2A>G NGS na
RP-2167 BBS BBS
CRD, obesity, 
polydactyly and 
brachydactyly, 
psychomotor and 
learning delay, and 
behaviour disorder
BBS2 NM_031885.2:c.471G>A; Affecting 5′ splicing site31
NM_031885.2:c.1237C>T;  
p.(Arg413*)30 NGS na
RP-2228 BBS BBS
RP, ID, overweight since 
infancy, brachydactyly, 
chronic renal failure, 
and renal transplant
BBS1 NM_024649.4:c.1645G>T; p.(Glu549*)33
NM_024649.4:c.118del;
p.(Cys40Alafs*2)62
MKKS 
NM_01884 
8.3:c.724G>T; 
p.(Ala242Ser)32
chip + NGS Y*
RP-1814 Joubert Joubert
RD, nystagmus, 
psychomotor delay, 
cerebellar atrophy, 
chronic renal failure, 
and macrocephaly
CEP290 NM_025114.3:c.4028del;p.(Lys1343Argfs*2)34
NM_025114.3:c.7341dup;
p.(Leu2448Thrfs*8)35 chip + NGS Y (AR)
Other specific syndromes
RP-1724 ZSSD ZSSD
Early RP, congenital 
deafness, neonatal 
jaundice, intrahepatic 
biliary dysgenesis, 
encephalopathy, ID, 
hiperprolactinemia, and 
gynecomastia
PEX1 NM_000466.2:c.2528G>A; p.(Gly843Asp)36
NM_000466.2:c.2528G>A; 
p.(Gly843Asp)36 NGS NA
V-0799 Pseudoxanthoma elasticum
Pseudoxanthoma 
elasticum
Macular atrophy, 
angioid streaks, and 
neovascular membrane
ABCC6
NM_001171.5:c.1483_1
485del;
p.(Leu495del)
NM_001171.5:c.1483_1485del;
p.(Leu495del) NGS Y (AR)
Miscellanea
RP-0485 RP + ID + deafness +  congenital malformations
Usher + Koolen 
de Vries
RP, mild ID, 
hearing loss, ASD, 
macrocephaly, and 
low-set ears
USH2A NM_206933.2:c.1876C>T; p.(Arg626*)43
NM_206933.2:c.13010C>T; 
p.(Thr4337Met)44
721Kb 
monosomy at 
17q21.31†
NGS + aCGH
Y (USH2A: 
AR CNV: de 
novo)
RP-1430 RP + ID Cohen RP and ID VPS13B NM_017890.4:c.1512del; p.(Glu505Lysfs*23)
NM_017890.4:c.1512del; 
p.(Glu505Lysfs*23) NGS Y*
RP-1613 RP + neuroendocrine alteration OTX2-related
LCA, congenital 
nystagmus, 
psychomotor delay, 
compulsive eating, 
muscular hypotonia, 
obesity, and 
hypogonadism
OTX2 NM_172337.2:c.255G>A; p.(Trp85*) NGS Y (de novo)
RP-2140 RP + neuroendocrine alteration OTX2-related
Congenital nystagmus, 
early-onset CRD, 
developmental delay, 
and panhypopituitarism
OTX2 NM_172337.2:c.559C>T;p.(Gln187*) NGS Y (de novo)
RP-2273 RP + neuroendocrine alteration BBS
Congenital nystagmus, 
LCA, developmental 
delay, congenital 
hypothalamic obesity, 
hypogonadism, 
acantosis nigricans, and 
clinodactyly
CEP41 NM_018718.2:c.5C>T;p.(Ser2Phe)
NM_018718.2:c.5C>T; 
p.(Ser2Phe) NGS na
Table 1. Clinical and genetic information of cases carrying likely disease-causal variants. Novel likely 
pathogenic variants found in this study are represented in bold. *Segregation of families RP-2228 and RP-
1430 could be only done in an unaffected sister and father, respectively. †Monosomy at 17q21.3 (arr[GRCh37] 
17q21.31(43417434_44138572)x1) encompassed the following genes: ARHGAP27, PLEKHM1, MIR4315-1, 
MIR4315-2, LRRC37A4, LOC101929001, DND1P1, LOC644172, RPS26P8, CRHR1, MGC57346, SPPL2C, 
MAPT, MAPT-IT1, STH, KANSL1. Abbreviations: aCGH: array–based comparative genomic hybridization; 
AR: autosomal recessive; ASD: atrial septal defect; BBS: Bardet-Biedl syndrome; CRD: cone-rod dystrophy; Dx: 
diagnosis; ID: intellectual disability; LCA: Leber congenital amaurosis; na: not available; NGS: next-generation 
sequencing; NPHP: nephronophthisis; RD: retinal dystrophy; RP: retinitis pigmentosa; Y: yes; ZSSD: Zellweger 
syndrome spectrum disorder. 
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most likely due to the presence of a second different pathogenic SNV in the father, that remains to be discovered 
after NGS sequencing. However, we cannot exclude the presence of additional non-coding variants that could 
explain the PXE phenotype.
Molecular Characterization of Clinically Unclassified Cases and Refinement of Clinical Diagnosis. 
Five cases (11%) were phenotypically reclassified based on our molecular findings and further clinical reas-
sessment (Table 1). Of them, 3 sporadic cases had common features of neuroendocrine disorder, psychomotor 
impairment, and Leber congenital amaurosis (LCA). It is noteworthy that 2 of these LCA cases (RP-1613 and 
RP-2140, Table 1), had diverse symptoms of hypopituitarism, and both bore de novo nonsense OTX2 variants: 
p.(Trp85*) and p.(Gln187*), respectively (Fig. 2). LOF variants in this transcription factor were previously asso-
ciated with a wide spectrum of pituitary dysfunction and congenital eye disorders ranging from anophthalmia 
to retinal dystrophies41. In a third sporadic LCA consanguineous patient (RP-2273, Table 1), an extremely rare 
missense variant, p.(Ser2Phe), was homozygously found in CEP41. This change affects a highly conserved resi-
due in the N-terminal domain of the ciliary protein CEP41 and was predicted as damaging by in silico analysis 
(Supplementary Table S3). Although CEP41 has previously been associated with Joubert syndrome42, no cere-
bellar abnormality was observed in the patient here reported, and his clinical picture (early-onset RD, mild ID, 
brachydactyly, and neuroendocrine alteration) was in principle more consistent with a BBS-like diagnosis.
In the sporadic case RP-0485, who had RD, neurosensorial hypoacusia, mild ID, and several congenital mal-
formations (Fig. 3 and Table 1), the co-occurrence of 2 rare genetic disorders was identified. First, NGS analysis 
identified 2 biallelic USH2A variants, both of which had previously been associated with Usher syndrome43,44, 
that were responsible for the retinal and hearing manifestations. Further high-resolution aCGH analysis enabled 
us to identify a 721-kb de novo microdeletion at 17q21.31 (Fig. 3), including the KANSL1 gene, which had been 
reported to cause Koolen-de Vries syndrome45. Finally, in a consanguineous Middle-Eastern patient (RP-1430) 
with RD and mental disability, a novel causative homozygous frameshift variant was found in the VPS13B gene, 
which is associated with Cohen syndrome. Unfortunately, a more accurate diagnosis could not be established, 
since few clinical data were available, and clinical re-evaluation of this patient could not be performed.
Discussion
ISRs comprise a diverse spectrum of highly heterogeneous and overlapping clinical conditions. Clinical diag-
nosis is often challenging, as some of the characteristic systemic features may not develop until later in infancy 
and adulthood or may even evolve and change over time. Several multigene panel approaches have been used 
for molecular characterization of specific retinal ciliopathies, such as BBS, Joubert syndrome, and Usher syn-
drome, yielding variable diagnostic rates7,18,19,46,47. Here, we first studied a more heterogeneous and large cohort 
of “non-naive”, i.e. previously screened ISR patients, who were all recruited in a single center, and were similar 
to those found in daily clinical practice. We included not only cases with a clear suspicion of syndromic forms of 
retinal disease, but also atypical cases that did not exactly fit any known ISR.
Our findings confirm the clinical utility of targeted NGS strategies, demonstrating an overall diagnostic rate 
of 30%, which is comparable with those obtained from similar studies using prescreened RD patients25,48. As 
expected from the heterogeneity of the cases included, the diagnostic yield obtained in the present ISR cohort was 
not uniform. While we obtained a high mutation detection rate (70%) in patients with clinically suspected specific 
ciliopathies, similar to previous studies46,47, the diagnostic rate decreased in patients with unspecific symptoms 
of ISR. Notably, the responsable molecular mechanism was identified in at least 5 of these patients, thus our 
study highlighted the potential of NGS to improve diagnostic accuracy in complex phenotypes. In this sense, 
the panel led us to clinically characterize 2 sporadic cases in which LCA was accompanied by neuroendocrine 
symptoms as bearing de novo OTX2 variants. The clinical symptoms of both cases overlapped with the previ-
ously OTX2-associated phenotypes, including pituitary dysfunction and retinal dystrophy49. Consequently, both 
Family Initial diagnosis Cytogenetic band
Rearrangement 
type
Genomic 
coordinates 
(hg19) Involved genes
Minimun Size 
(kb) Method Validation Causality
Additional genetic 
findings
RP-0485 RP + ID + deafness +  congenital malformations 17q21.31 monosomy
chr17:43417434–
44138572
ARHGAP27,  
PLEKHM1,  
MIR4315-1,  
MIR4315-2,  
LRRC37A4, 
LOC101929001, 
DND1P1,  
LOC644172,  
RPS26P8,  
CRHR1,  
MGC57346,  
SPPL2C, MAPT,  
MAPT-IT1, STH, 
KANSL1
721 aCGH yes Yes (Koolen de Vries)
Biallelic USH2A 
variants, responsible 
of Usher related 
symptoms
RP-1581 RP + ID + various disorders 11q13.2 whole gene duplication
chr11: 66277760–
66300760 BBS1 23 NGS + aCGH yes VUS
in cis with a VUS in 
BBS1(maternally 
inherited)
RP-2009 RP + ID + various disorders 14q11.2 exon 17–19 deletion
chr14:21795786–
21798554 RPGRIP1 2,77 NGS + MLPA yes Unlikely
Biallelic SCAPER 
variants55
Table 2. Copy Number Variants found by coverage depth analysis or array–based comparative genomic 
hybridization. aCGH: array–based comparative genomic hybridization; ID: intellectual disability; NGS: next-
generation sequencing; RP: retinitis pigmentosa; VUS: variant of uncertain significance.
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patients were also genetically reclassified as having a condition based on dominant inheritance. The identification 
of de novo events highlights the relevance of obtaining a correct genetic diagnosis in sporadic genetic cases as first 
step to enable a more accurate genetic counseling50.
We were able to reclassify a miscellaneous case within the ciliopathy group owing to the identification of a 
novel homozygous likely causal CEP41 variant. Although this ciliary gene was previously associated with Joubert 
syndrome42, this sporadic case had RP with neuroendocrine symptoms that seemed to be more compatible with a 
BBS-like form. In addition, the normal brain MRI scan in this patient excluded Joubert syndrome as clinical diag-
nosis. Furthermore, we found biallelic pathogenic variants in the IFT27 gene in a BBS patient. To our knowledge, 
this is the second case of BBS bearing IFT27 alterations in the literature29.
In 9 cases, we found only a monoallelic likely pathogenic variant in a well-known recessive gene. The presence 
of a second pathogenic variant was not fully excluded, as it might reside in deep intronic, regulatory, and even 
highly repetitive regions that were not targeted in our gene panel. The clinical presentation in most cases was 
reasonably consistent with the phenotypic features of the suspected gene. For instance, 3 of 11 ciliopathy-like 
patients carried heterozygous pathogenic variants in ciliopathy genes, such as ALSM1, USH2A, and WDPCP, thus 
it might support the initial clinical suspicion. Therefore, some of these inconclusive genetic findings could also 
be helpful to guide further management and follow-up of these patients. However, additional molecular analysis 
of the above-mentioned unexplored regions should be performed using custom targeted resequencing or even 
whole-genome sequencing (WGS).
Structural variants also represent an underestimated mutational burden that contributes to missing heritabil-
ity and oligogenic mechanisms, not only in non-syndromic RD, but also in BBS and Joubert syndrome20,24–26,51,52. 
Here, we report novel heterozygous multi-exon structural variants for BBS1 and RPGRIP1 that were identified by 
targeted comparative read-depth analysis. However, their possible causality is unclear, since no second pathogenic 
allele was found in trans in these genes. Therefore, additional studies would be necessary to determine whether 
the variants represent random background variation or contribute to the disease. Nonetheless, our results also 
suggest that CNV and re-sequencing studies are both required to fully delineate the complexity of disease archi-
tecture in ISR phenotypes.
The low diagnostic rate found in cases with suspected atypical ciliopathies or complex presentations also 
suggests the participation of additional genes not present in the panel, whether novel candidate genes or genes 
recently associated with ISRs (e.g. CEP120 or GRID2)53,54. Further whole-exome sequencing (WES) or WGS 
could prove useful for characterization of additional patients in our cohort. In this sense, biallelic pathogenic var-
iants were identified in SCAPER, a novel RD gene explaining RP with ID, in 2 uncharacterized cases of the miscel-
laneous group, as we recently published55. An additional plausible mechanism that could explain some negative 
Figure 2. Pedigrees and co-segregation analysis for cases carrying likely disease-causing variants. Genotype of 
each available family member is represented below the individual symbol being “+” normal allele, and “m, m1, 
m2, and m3”, mutated alleles.
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cases with a complex phenotypic spectrum is the possibility of multiple clinical diagnoses due to the co-existence 
of molecular defects in several disease-causing genes. Dual molecular diagnosis was recently reported in at least 
4% of cases with informative WES22,56. Here, we observed co-occurrence of Usher syndrome and Koolen de Vries 
syndrome, each segregating independently as recessive and de novo events, respectively. Biallelic USH2A vari-
ants, first identified by NGS, were responsible for RP and neurosensorial hypoacusia, but they do not completely 
explain the phenotypic complexity of this case. Other features, such as mild ID, atrial septal defect, macrocephaly 
and low-set ears, were caused by a coexistent de novo 17q21.31 microdeletion, including the KANSL1 gene, which 
is associated with Koolen-de Vries syndrome45. Thus, further NGS testing of non-syndromic associated RD genes 
in combination with aCGH analysis may prove very useful for ruling out the co-existence of several genetic events 
in uncharacterized atypical cases22.
Our study highlights the huge potential of genetic testing to obtain prompt molecular diagnoses in complex 
ISR cases using relatively low-cost, robust, accurate, and clinically useful multigene NGS panels and CNV analy-
sis. Thus, this combined strategy increased our understanding of well-defined phenotypes of ISR, such as retinal 
ciliopathies. Implementation in routine clinical practice of similar approaches based on NGS panels with a wider 
gene spectrum including not only reported RD and ciliary genes, but also genes associated with other retinal con-
ditions, would reduce the time and cost of diagnosing ISRs and provide an earlier diagnosis of systemic features, 
even before they appear. This is especially important for clinical follow-up in medically actionable diseases and 
also for enrollment of patients in future gene therapy–based treatments. Alternatively, clinical or WES seems to 
be a very useful choice for cases presenting with more unspecific or widely complex ISR phenotypes and could 
potentially improve molecular diagnostic yields.
Figure 3. Dual diagnosis of Usher and Koolen de Vries syndromes in case index of family RP-0485 by targeted 
NGS and array–based comparative genomic hybridization (aCGH) (A). Pedigree and segregation analysis for 
genetic findings showed a recessive inheritance for biallelic pathogenic USH2A variants and a de novo CNV. 
Genotype of each available family member is represented below the individual symbol being “ + ” normal allele, 
and “m1, m2, and m3”, mutated alleles. Electropherograms of heterozygous carrier and wild-type individual for 
USH2A variants in exons 11 and 63 were also shown (B). Genomic rearrangement on 17q21.31 region identified 
in by aCGH. Chromosome and gene views of the affected chromosome show an aberrant deletion of minimum 
size of 721Kb (genomic coordinates: chr17:43,417,434-44,138,572) and maximum ~1,4 Mb (chr17:43,398,423-
44,841,644), which is highlighted in dark and light red colour, respectively. An abnormal pattern of one copy 
was observed for 80 probes covering 16 genes (ARHGAP27, PLEKHM1, MIR4315-1, MIR4315-2, LRRC37A4, 
LOC101929001, DND1P1, LOC644172, RPS26P8, CRHR1, MGC57346, SPPL2C, MAPT, MAPT-IT1, STH, 
KANSL1). The vertical axis shows the position along the genome (hg19) and the horizontal axis the log2 
intensity ratio values (−2/−1: deletions, 0: normal pattern, + 1/ + 2: duplications).
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Materials/Subjects and Methods
Clinical diagnosis and sample collection. We selected genetically non-characterized patients with 
syndromic retinopathies from our database of RD patients who attended Fundación Jiménez Díaz University 
Hospital (FJD, Madrid, Spain) in the last 25 years. We excluded typical Usher syndrome patients, as they were 
already assessed using a specific NGS Usher gene panel47. The clinical diagnosis was made according to previ-
ously established criteria and included ophthalmic, physical, and additional examinations10,12,14,57,58. The cohort 
included cases with various suspected patterns of inheritance, including autosomal recessive, autosomal domi-
nant, and sporadic cases. This study was reviewed and approved by the FJD Ethics Committee and was performed 
according to the tenets of the Declaration of Helsinki and its reviews. The participants, or their legal guardians, 
signed a written informed consent form before the study. DNA samples were collected from FJD Biobank.
Clinical Genetic Testing. Following routine clinical procedures, all patients had previously been screened 
using commercial genotyping microarrays (AsperBiotech, Tartu, Estonia) for previously known pathogenic var-
iants in several genes associated with BBS, Alström syndrome, LCA, or autosomal recessive retinitis pigmentosa. 
In cases compatible with BBS or Alström syndrome, Sanger-sequencing was performed to screen for the most 
prevalent mutated exons and/or genes, as previously reported57,58. Homozygosity mapping studies were also per-
formed in some families57,59.
Target Enrichment and Bioinformatic Analysis. Gene Panel Design, Library Construction, and 
Sequencing. A custom targeted NGS approach was designed to specifically study ISR patients using the Nextera 
Rapid Capture kit (Illumina, Cambridge, UK) for target enrichment. The DesignStudio software tool (Illumina) 
was used to design the gene panel. We selected genes based on previous associations with ISRs, including 86 
genes reported in the Retnet database (data accession in 2015) and 17 genes after a thorough revision of litera-
ture. In addition, 18 very likely candidate genes were also included due to their previously involvement in other 
non-syndromic ciliopathies.
Many of them show a high degree of phenotypic overlap and appear to be functionally related (Supplementary 
Fig. S1). The complete list of genes targeted is detailed in Supplementary Table S1 and includes the following: i) 
71 ciliopathy-related genes accounting for RD and multisystemic disease; ii) 18 ciliary genes previously impli-
cated in non-syndromic RD or associated with non-retinal ciliopathies, such as isolated nephronophthisis, were 
also added as likely candidate genes; and iii) 32 non-ciliopathy genes including PBDs and lysosomal disorders (5 
genes), syndromic vitreoretinopathies (7 genes), and a miscellanea of syndromic retinal alterations with overlap-
ping systemic features (20 genes). The gene panel included coding and non-coding exons and targeted flanking 
upstream and downstream 50-bp and 5′ and 3′ UTR regions and also known deep intronic variants previously 
identified in the BBS1, CEP290, OFD1, and USH2A genes (Supplementary Table S4). In total, the library con-
tained 2,459 target regions covered by 3,813 probes spanning 577 kb.
Libraries for 47 samples were prepared following the manufacturer’s protocol. Briefly, DNA samples were 
quantified using fluorometric assays (PicoGreen, Invitrogen, Thermo Fisher Scientific, MA, USA) and normal-
ized to prepare 50 ng of starting material at 5 ng/µl. Samples were tagmented, PCR amplified, and cleaned up. 
Libraries were pooled with 24 samples, multiplexed, hybridized for 90 min, and captured. A second round of 
hybridization, capture, PCR amplification, and clean-up was performed. Final libraries were quantified using 
qPCR with the KAPA Library Quantification Kit (Kapa Biosystems, London, UK) and validated by capillary 
electrophoresis using a 2100 Bionalyzer (Agilent Technologies, Santa Clara, CA, USA). Finally, 1.8 pm of 24 equi-
molecularly pooled libraries were loaded into a NextSeq500 flow cell and sequenced using the NextSeq500 Mid 
Output reagents Kit v1 (Illumina, Cambridge, UK) to obtain 150-bp paired-end reads. The sequencing had an 
average coverage of 435X with approximately 85% reads on target, and 93% of target regions of these 121 genes 
were completely covered (Supplementary Fig. S3).
The affected father (I:1) from family V-0799 has also been analyzed using targeted clinical exome. Libraries 
were prepared using TruSightOne (Illumina) following the manufacturer’s protocol. The captured libraries were 
sequenced with Illumina NextSeq500 with 150-bp paired-end reads.
Bioinformatic Analyses. A specific custom pipeline for Illumina Nextera technology implemented on the com-
mercial DNAnexus platform (https://www.dnanexus.com/) was used for the bioinformatics analysis as previ-
ously described25,48. Briefly, Prinseq-lite v0.20.3 was used to calculate read statistics, and BWA-MEM v0.7.5a with 
default parameters was used to map the reads. Samtools v0.19 was then used to sort and index the BAM files, and 
Picard MarkDuplicates v1.119 was used to mark duplicates. Freebayes v9.9.13 was used for variant calling, Picard 
CalculateHSMetrics v1.119 to calculate metrics, and BedTools and custom code to determine minimum cover-
age. Identified variants were annotated using GATK v2.4. Gene coverage was calculated using BedTools to extract 
the number of reads overlapping any genome region from the BAM file of each sample. From this, coverage was 
calculated per gene and sample by counting the reads per nucleotide inside the gene coordinates. Regions with a 
coverage of fewer than 10 reads were excluded.
To verify the reliability of our targeted NGS approach, we used a validation cohort consisting of 5 out of the 
total 47 patients analyzed, which carried 6 different heterozygous variants previously detected by genotyping 
microarray (Supplementary Table S5). All variants used as controls were correctly identified.
A CNV analysis was performed with NGS data following the previously reported CoNVaDING method, 
which had been specifically developed for gene panel data at high-coverage and enables accurately single-exon 
detection60. Briefly, it uses the average coverage of each specified target to perform calculations starting from 
BAM files. Then, it selects a group of control samples with the coverage pattern that is most similar to that of the 
sample to be analyzed, which are used in the normalization step. Finally, it performs a filtering step that renders 
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the list with deletions and duplications. The method includes QC metrics that make it possible to distinguish 
high-quality from low-quality samples60.
Variant Prioritization and Classification. Potentially pathogenic variants were sequentially assessed as previously 
described25,48, based on the following criteria: i) variants previously reported as pathogenic in mutation databases, 
including HGMD Professional (http://www.biobase-international.com/product/hgmd) and the Leiden Open 
Variation Database (http://www.lovd.nl/3.0/home); ii) LOF variants such as nonsense, frameshift, and those located 
at the canonical splice site; iii) variants filtered out, focusing on rare variants with a minor allele frequency (MAF) 
≤0.005 in 1000 Genomes (http://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/), Exome Variant Server 
(EVS) (http://evs.gs.washington.edu/EVS/), ExAC Browser (http://exac.broadinstitute.org/), and CIBERER Spanish 
Variant Server (http://csvs.babelomics.org/); iv) missense SNV and in-frame deletions that induced an alteration in 
the protein predicted as pathogenic in at least 2 of the in silico tools used to predict pathogenicity (SIFT, Polyphen2, 
Mutation Taster, Align GVGD, PROVEAN); v) non-canonical splicing variants in silico predicted to cause a dele-
terious effect by several splicing tools (Human Splicing Finder, MaxEntScan, Splice Site Finder-like, NNSPLICE, 
GeneSplicer, ESEFinder); vi) genes associated with the most likely clinical phenotype in each case. Alamut software 
(Interactive Biosoftware, Rouen, France) was used to infer in silico predictions of variant pathogenicity.
Validation Studies. Sequence variants of interest identified by NGS were verified and segregated in the 
respective families by Sanger sequencing following PCR amplification of the respective coding exons and adjacent 
intronic sequences by standard protocols (primers are available on request).
Multiplex Ligation-dependent Probe Amplification (MLPA) analysis. MLPA was performed 
according to manufacturer instructions using commercially available kits (MRC-Holland, Amsterdam, 
Netherlands). The RPGRIP1 deletion on exons 17–19 was validated using MLPA SALSA p222 covering exons 18 
and 19. The MLPA SALSA P092 was used to rule out CNVs in the ABCC6 gene. The amplified fragments were 
separated by capillary electrophoresis through an ABI 3130xl automatic analyzer (Applied Biosystems) and ana-
lyzed using GeneMapper (Applied Biosystems) and Coffalyser (MRC-Holland) software programs.
Array–based comparative genomic hybridization. Contiguous gene deletion syndromes was assessed by 
means of aCGH in 14 patients with atypical complex phenotypes in which RD was accompanied by ID and/or con-
genital malformations. The aCGH analysis was performed using the Agilent SurePrint G3 CGH + SNP Microarray Kit 
2 × 400 K (Agilent Technologies, Santa Clara, CA, USA), which contains 292 097 CGH probes and 119 091 SNP probes 
with median spacing of 7.2 kb. The CGH probes are gene- and exon-biased, focusing coverage on regions of clinical 
interest in the genome. Briefly, genomic DNA (500 ng) from the patient and from a sex-matched control were labeled 
with Cy3-dUTP and Cy5-dUTP fluorochromes using the Sure Tag DNA Labeling Kit (Agilent Technologies), and fur-
ther hybridized on microarray according to Agilent protocols. The slide was scanned on a SureScan G4 900DA scanner 
(Agilent Technologies). TIFF image was analyzed using Agilent CytoGenomics v.2.7 based.
Haplotype Analysis. Five polymorphic microsatellite markers on 16p13.13-p12.1 with high heterozygo-
sity (D16S3075, D16S3103, D16S3046, D16S420 and D16S3068) flanking around 13 Mb (chr16:12,115,341-
25,549,627) of the ABCC6 gene were used to investigate the IBD mechanism in the family V-0779. For the STR 
genotyping, PCR products were analyzed using the automated ABI 3130xl Genetic Analyzer (Applied Biosystems) 
and further analyzed with the GeneMapper v3.5 software (Applied Biosystems). Haplotype reconstruction was 
performed using the software Cyrillic ver. 2.1 (Cyrillic Software, Wallingford, UK).
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